Profusa Advances CE Mark Review for Lumee Oxygen Platform with GMED Submission
Event summary
- Profusa submitted a response package to GMED on June 12, 2026, addressing questions from the CE Mark review process for the Lumee Oxygen Platform.
- The submission included updates on technical documentation, quality system evidence, clinical evaluation activities, and validation information.
- The Lumee Oxygen Platform is designed for continuous, real-time tissue oxygen monitoring, targeting unmet clinical needs.
- Profusa aims to commercialize the technology in Europe pending GMED's assessment, which remains ongoing with no guaranteed timeline.
The big picture
Profusa's submission to GMED is a critical step in its strategy to expand into Europe with the Lumee Oxygen Platform, a technology that could disrupt traditional tissue oxygen monitoring methods. The success of this regulatory milestone will determine the company's ability to tap into a market where continuous, real-time monitoring is increasingly valued for critical care and chronic disease management. The broader trend of digital health innovation in Europe hinges on such regulatory approvals, making this a key indicator of Profusa's growth trajectory.
What we're watching
- Regulatory Timing
- Whether GMED's review process will conclude within Profusa's anticipated timeline, given the lack of assurances on the assessment's duration.
- Market Readiness
- How the Lumee Oxygen Platform will position itself in Europe's competitive tissue oxygen monitoring market upon approval.
- Commercialization Strategy
- The pace at which Profusa can scale manufacturing and distribution to meet European demand post-CE Mark.
Related topics